Drug Profile
Research programme: eye disorder therapies - Oyster Point Pharmaceuticals
Alternative Names: OC-03; OC-04Latest Information Update: 13 Jan 2023
Price :
$50
*
At a glance
- Originator Oyster Point Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Corneal disorders
Most Recent Events
- 03 Jan 2023 Oyster Point Pharmaceuticals has been acquired by Viatris Inc
- 28 Aug 2022 No recent reports of development identified for preclinical development in Corneal-disorders in USA
- 02 Jul 2018 Preclinical trials in Corneal disorders in USA (unspecified route) (Company pipeline, July 2018)